Team:USTC CHINA

From 2013.igem.org

(Difference between revisions)
Line 92: Line 92:
   We hope to develop a fresh-expression transdermal vaccination.
   We hope to develop a fresh-expression transdermal vaccination.
   <br />We hope everyone in this world could equally enjoy the benefit of medical progress.<br />
   <br />We hope everyone in this world could equally enjoy the benefit of medical progress.<br />
-
   <a href="https://2013.igem.org/Team:USTC_CHINA/Project/ProjectDetails/Background">more about project background</a>
+
   <a href="https://2013.igem.org/Team:USTC_CHINA/Project/ProjectDetails/Background">more</a>
   </div>
   </div>
   <img class="img-right" src="https://static.igem.org/mediawiki/2013/8/8e/2013ustc-china_99.png" width="16" height="13" /></div>
   <img class="img-right" src="https://static.igem.org/mediawiki/2013/8/8e/2013ustc-china_99.png" width="16" height="13" /></div>
Line 108: Line 108:
As the core of our in-situ system,<br /> TD1-antigen expresser is designed<br /> and will share a great percentage of<br /> the total bacteria in our "band-aid".
As the core of our in-situ system,<br /> TD1-antigen expresser is designed<br /> and will share a great percentage of<br /> the total bacteria in our "band-aid".
<br />
<br />
-
   <a href="https://2013.igem.org/Team:USTC_CHINA/Project/ProjectDetails/Design">more about project design</a>
+
   <a href="https://2013.igem.org/Team:USTC_CHINA/Project/ProjectDetails/Design">more</a>
   </div>
   </div>
   <img class="img-right" src="https://static.igem.org/mediawiki/2013/8/8e/2013ustc-china_99.png" width="16" height="13" />
   <img class="img-right" src="https://static.igem.org/mediawiki/2013/8/8e/2013ustc-china_99.png" width="16" height="13" />
Line 118: Line 118:
As one kind of our adjuvant expresser,<br />TD1-LTB is used to enhance the antigenicity.<br /> For LTB has so many advantages, it's a wild using adjuvant for most of exsiting injected vaccine.
As one kind of our adjuvant expresser,<br />TD1-LTB is used to enhance the antigenicity.<br /> For LTB has so many advantages, it's a wild using adjuvant for most of exsiting injected vaccine.
<br />
<br />
-
   <a href="https://2013.igem.org/Team:USTC_CHINA/Project/ProjectDetails/Design">more about project design</a>
+
   <a href="https://2013.igem.org/Team:USTC_CHINA/Project/ProjectDetails/Design">more</a>
   </div>
   </div>
   <img class="img-right" src="https://static.igem.org/mediawiki/2013/8/8e/2013ustc-china_99.png" width="16" height="13" />
   <img class="img-right" src="https://static.igem.org/mediawiki/2013/8/8e/2013ustc-china_99.png" width="16" height="13" />
Line 128: Line 128:
It's worth mentioning that to improve the effects of <br />traditional vaccine, as another kind of our TD1-adjuvant expresser, KNFα bear the weight of our hope to increase the sensitivity of our immune system.
It's worth mentioning that to improve the effects of <br />traditional vaccine, as another kind of our TD1-adjuvant expresser, KNFα bear the weight of our hope to increase the sensitivity of our immune system.
<br />
<br />
-
   <a href="https://2013.igem.org/Team:USTC_CHINA/Project/ProjectDetails/Design">more about project design</a>
+
   <a href="https://2013.igem.org/Team:USTC_CHINA/Project/ProjectDetails/Design">more</a>
   </div>
   </div>
   <img class="img-right" src="https://static.igem.org/mediawiki/2013/8/8e/2013ustc-china_99.png" width="16" height="13" />
   <img class="img-right" src="https://static.igem.org/mediawiki/2013/8/8e/2013ustc-china_99.png" width="16" height="13" />
Line 138: Line 138:
Reporter, which notifies users whether the status of vaccine patch is all right and when they can stick the patches to arms .  Further more killing switch is existed in them as a biosafety guard.
Reporter, which notifies users whether the status of vaccine patch is all right and when they can stick the patches to arms .  Further more killing switch is existed in them as a biosafety guard.
<br />
<br />
-
   <a href="https://2013.igem.org/Team:USTC_CHINA/Project/ProjectDetails/Design">more about project design</a>
+
   <a href="https://2013.igem.org/Team:USTC_CHINA/Project/ProjectDetails/Design">more</a>
   </div>
   </div>
   <img class="img-right" src="https://static.igem.org/mediawiki/2013/8/8e/2013ustc-china_99.png" width="16" height="13" />
   <img class="img-right" src="https://static.igem.org/mediawiki/2013/8/8e/2013ustc-china_99.png" width="16" height="13" />
Line 151: Line 151:
  <span>Molecules part</span><br />
  <span>Molecules part</span><br />
We took E.coli and the PET vector as the positive control and realized our ideas in the B.subtilis expression system based on PHT43 shuttle vector.<br />
We took E.coli and the PET vector as the positive control and realized our ideas in the B.subtilis expression system based on PHT43 shuttle vector.<br />
-
   <a href="https://2013.igem.org/Team:USTC_CHINA/Project/Results">more about project results</a>
+
   <a href="https://2013.igem.org/Team:USTC_CHINA/Project/Results">more</a>
   </div>
   </div>
   <img class="img-right" src="https://static.igem.org/mediawiki/2013/8/8e/2013ustc-china_99.png" width="16" height="13" />
   <img class="img-right" src="https://static.igem.org/mediawiki/2013/8/8e/2013ustc-china_99.png" width="16" height="13" />
Line 160: Line 160:
   <span>Protein part</span><br />
   <span>Protein part</span><br />
   Before we achieve fresh expression, we need first use purified protein to obtain exact data to verify our assumption.<br />
   Before we achieve fresh expression, we need first use purified protein to obtain exact data to verify our assumption.<br />
-
   <a href="https://2013.igem.org/Team:USTC_CHINA/Project/ProjectDetails/Results">more about project results</a>
+
   <a href="https://2013.igem.org/Team:USTC_CHINA/Project/ProjectDetails/Results">more</a>
   </div>
   </div>
   <img class="img-right" src="https://static.igem.org/mediawiki/2013/8/8e/2013ustc-china_99.png" width="16" height="13" />
   <img class="img-right" src="https://static.igem.org/mediawiki/2013/8/8e/2013ustc-china_99.png" width="16" height="13" />
Line 169: Line 169:
   <span>Mice experiments</span><br />
   <span>Mice experiments</span><br />
   The most obvious character of our 2013USTC iGEM team is that we have not only achieved a series of molecule experiments but also tried mice experiments, which could be divided into transdermal experiments in vitro and animate mice experiments<br />
   The most obvious character of our 2013USTC iGEM team is that we have not only achieved a series of molecule experiments but also tried mice experiments, which could be divided into transdermal experiments in vitro and animate mice experiments<br />
-
   <a href="https://2013.igem.org/Team:USTC_CHINA/Project/Results/FurthurWork">more about project results</a>
+
   <a href="https://2013.igem.org/Team:USTC_CHINA/Project/Results/FurthurWork">more</a>
   </div>
   </div>
   <img class="img-right" src="https://static.igem.org/mediawiki/2013/8/8e/2013ustc-china_99.png" width="16" height="13" />
   <img class="img-right" src="https://static.igem.org/mediawiki/2013/8/8e/2013ustc-china_99.png" width="16" height="13" />

Revision as of 18:18, 27 September 2013

USTC_China

In Situ Transdermal Vaccine

Fresh Expression, No Purification
Standardization, Block-based design
Easy-transportation, Low Storage External Costs
Almost No Demand For Medical Conditions And Proferssionals

Project

Motivation

We hope to develop a fresh-expression transdermal vaccination.
We hope everyone in this world could equally enjoy the benefit of medical progress.
more

Design of Project

With the support of TD-1, a special polypeptide which can greatly facilitate macromolecule transdermal delivery through intact skin, we construct three different fuctional engineered bacillus subtilis; besides, we design a reporter system, including a kill switch, in the fouth type B.subtilis to improve usability and ensure biosafety.
ANTIGEN
As the core of our in-situ system,
TD1-antigen expresser is designed
and will share a great percentage of
the total bacteria in our "band-aid".
more
LTB
As one kind of our adjuvant expresser,
TD1-LTB is used to enhance the antigenicity.
For LTB has so many advantages, it's a wild using adjuvant for most of exsiting injected vaccine.
more
TNFα
It's worth mentioning that to improve the effects of
traditional vaccine, as another kind of our TD1-adjuvant expresser, KNFα bear the weight of our hope to increase the sensitivity of our immune system.
more
REPORTER
Reporter, which notifies users whether the status of vaccine patch is all right and when they can stick the patches to arms . Further more killing switch is existed in them as a biosafety guard.
more

Experimental Measurement

Molecules part
We took E.coli and the PET vector as the positive control and realized our ideas in the B.subtilis expression system based on PHT43 shuttle vector.
more
Protein part
Before we achieve fresh expression, we need first use purified protein to obtain exact data to verify our assumption.
more
Mice experiments
The most obvious character of our 2013USTC iGEM team is that we have not only achieved a series of molecule experiments but also tried mice experiments, which could be divided into transdermal experiments in vitro and animate mice experiments
more

Retrieved from "http://2013.igem.org/Team:USTC_CHINA"